Regulatory T-cells in chronic lymphocytic leukemia and autoimmune diseases

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 4, Issue 1, 2012, Pages

  D'Arena, Giovanni ^a   Rossi, Giovanni ^b   Vannata, Barbara ^c   Deaglio, Silvia ^d   Mansueto, Giovanna ^a   D'Auria, Fiorella ^a   Statuto, Teodora ^a   Simeon, Vittorio ^a   De Martino, Laura ^e   Marandino, Aurelio ^e   Poeta, Giovanni Del ^f   De Feo, Vincenzo ^e   Musto, Pellegrino ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF SALERNO   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLUDARABINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; LENALIDOMIDE; T LYMPHOCYTE RECEPTOR; THALIDOMIDE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER PROGNOSIS; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INNATE IMMUNITY; LYMPHOCYTE TRANSFER; PREDICTION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; T CELL DEPLETION; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY;

EID: 84875967137     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2012.053     Document Type: Review

References (65)

1. Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med 2006; 354: 1166-1176. http://dx.doi.org/10.1056/NEJMra055446 PMid:16540617
2. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133: 775-787. http://dx.doi.org/10.1016/j.cell.2008.05.009 PMid:18510923
3. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108: 804-811. http://dx.doi.org/10.1182/blood-2006-02-002774 PMid:16861339
4. Gershon R, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970; 18: 723-737. PMid:4911896 PMCid:1455602
5. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic tolerance maintained by activated T cells expressing IL-2 receptor a-chain (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164. PMid:7636184
6. Robb RJ, Munck A, Smith KA. T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med 1981; 154: 1455-1474. http://dx.doi.org/10.1084/jem.154.5.1455 PMid:6975347 PMCid:2186509
7. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245-1253. PMid:11466340
8. Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+CD25+ regulatory T cells. Semin Immunol 2004; 16: 89-97. http://dx.doi.org/10.1016/j.smim.2003.12.005 PMid:15036232
9. Baecher-Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease. Immunol Rev 2006; 212: 203-216. http://dx.doi.org/10.1111/j.0105-2896.2006.00417.x PMid:16903916
10. Singh B, Read S, Asseman C, Malstrom V, Mottet C, Stephens LA, Stepankova R, Tlaskalova H, Powrie F. Control of intestinal inflammation by regulatory T cells. Immunol Rev 2001; 182: 190-200. http://dx.doi.org/10.1034/j.1600-065X.2001.1820115.x PMid:11722634
11. Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol 2007; 19: 217-223. http://dx.doi.org/10.1016/j.coi.2007.02.004 PMid:17306521
12. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol 2005; 6: 353-360. http://dx.doi.org/10.1038/ni1181 PMid:15785761
13. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor FoxP3. Science 2003; 299: 1057-1061. http://dx.doi.org/10.1126/science.1079490 PMid:12522256
14. Fontenot JD, Gavin MA, Rudensky AY. FOXP3 programs the development and function of CD4+CD25+ regulatory T-cells. Nat Immunol 2003; 4: 330-336. http://dx.doi.org/10.1038/ni904 PMid:12612578
15. Rudensky AY, Fontenot JD. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor FoxP3. Nature Immunol 2005; 6: 331-337. http://dx.doi.org/10.1038/ni1179 PMid:15785758
16. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B. Expression of interleukin (IL)-2 and IL-7 receptors discriminate between human regulatory and activated T cells. J Exp Med 2006; 203: 1693-1700. http://dx.doi.org/10.1084/jem.20060468 PMid:16818676 PMCid:2118333
17. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J Exp Med 2006; 203: 1700-1711. http://dx.doi.org/10.1084/jem.20060772 PMid:16818678 PMCid:2118339
18. Dejaco C, Duftner C, Grubeck-Loebenstein B, Schirmer M. Imbalance of regulatory cells in human autoimmune diseases. Immunology 2005; 117: 289-300. http://dx.doi.org/10.1111/j.1365-2567.2005.02317.x PMid:16476048 PMCid:1782226
19. Hafler DA, de Jager PL. Applying a new generation of genetic maps to understand human inflammatory disease. Nat Rev Immunol 2005; 5: 83-91. http://dx.doi.org/10.1038/nri1532 PMid:15630431
20. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 8-27. http://dx.doi.org/10.1111/j.0105-2896.2006.00427.x PMid:16903903
21. Godfrey VL, Wilkinson JE, Russell LB. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am J Pathol 1991; 138: 1379-1387. PMid:2053595 PMCid:1886400
22. Viglietta V, Baecher-Allan C, Weiner HL, Hfler DA. Loss of cunctional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 971-979. http://dx.doi.org/10.1084/jem.20031579 PMid:15067033 PMCid:2211881
23. Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou YK, Bourdette D, Ziegler SF, Offner H, Vandenbark AA. Decreased FOXP3 in multiple sclerosis patients. J Neurosci Res 2005; 81: 45-52. http://dx.doi.org/10.1002/jnr.20522 PMid:15952173
24. Kriegel MA, Lohamann T, Gabler C, Blank N, Kalden JR, Lorenz HM. Defective suppressor function of human CD4+CD25+ regulatory T cells in autoimmune polygranular T cells in autoimmunepolygrandular syndrome type II. J Exp Med 2004; 199: 1285-1891. http://dx.doi.org/10.1084/jem.20032158 PMid:15117972 PMCid:2211900
25. Balandina A, Lecart S, Dartevelle P, Saoudi A, Berrih-Aknin S. Functional defect of regulator CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005; 105: 735-41. http://dx.doi.org/10.1182/blood-2003-11-3900 PMid:15454488 PMCid:1847365
26. Ono M, Shimizu J, Miyachi Y, Sakaguchi S. Control of autoimmune myocarditis and multi-organ inflammation by GITRhigh FoxP3- expressing CD25+ and CD25- regulatory T cells. J Immunol 2006; 176: 4748-4756. PMid:16585568
27. Horak I, Lohler J, Ma A, Smith KA. Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol Rev 1995; 148: 35-44. http://dx.doi.org/10.1111/j.1600-065X.1995.tb00092.x PMid:8825281
28. Aschenbrenner K, D'Cruz LH, Vollmann EH, Hintenberger M, Emmerich J, Swee LK, Rolink A, Klein L. Selection of FoxP3 regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nature Immunol 2007; 8: 351-358. http://dx.doi.org/10.1038/ni1444 PMid:17322887
29. Piccirillo CA, Thornton AM. Cornerstone of peripheral tolerance: naturally occurring CD4+CD24+ regulatory T cells. Trends Immunol 2004; 25: 374-380. http://dx.doi.org/10.1016/j.it.2004.04.009 PMid:15207505
30. Corthay A. How do regulatory T cells work? Scand J Immunol 2009; 70: 326-336. http://dx.doi.org/10.1111/j.1365-3083.2009.02308.x PMid:19751267 PMCid:2784904
31. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009; 21: 1105-1111. http://dx.doi.org/10.1093/intimm/dxp095 PMid:19737784
32. Thornton AM, Shevac EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188: 287-296. http://dx.doi.org/10.1084/jem.188.2.287 PMid:9670041 PMCid:2212461
33. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, Shimizu J, Jakaguchi J. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998; 10: 1969-1980. http://dx.doi.org/10.1093/intimm/10.12.1969 PMid:9885918
34. Walunas TL, Bluestone JA. CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J Immunol 1998; 160: 3855-3860. PMid:9558090
35. Shimuzu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3: 135-142. http://dx.doi.org/10.1038/ni759 PMid:11812990
36. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden K, Oukka M, Kuchroo VK, Strom TB, Robson SC. Adenosine generations catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265. http://dx.doi.org/10.1084/jem.20062512 PMid:17502665 PMCid:2118603
37. Geissmann F, Revy P, Regnault A, Lepelletier Y, Dy M, Brousse N, Amigorena S, Hermine O, Durandy A. TGF-beta 1 prevents the noncognate maturation of human dendritic Langherans cells. J Immunol 1999; 162: 4567-4575. PMid:10201996
38. Strobl H, Knapp W. TGF-β1 regulation of dendritic cells. Microbes Infection 1999; 1: 1283-1290. http://dx.doi.org/10.1016/S1286-4579(99)00256-7
39. Shevac EM. CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2: 389-400. PMid:12093005
40. Taylor A, Vehagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β: the role of T regulatory cells. Immunol 2006; 117: 443-442.
41. Levings MK, Bacchetta R, Schulz U, Roncarolo MG. The role of IL-10 and TGF-β in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002; 129: 263-276. http://dx.doi.org/10.1159/000067596 PMid:12483031
42. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004; 21: 589-601. http://dx.doi.org/10.1016/j.immuni.2004.09.002 PMid:15485635
43. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Levy TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 2004; 104: 2840-2848. http://dx.doi.org/10.1182/blood-2004-03-0859 PMid:15238416
44. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815. http://dx.doi.org/10.1056/NEJMra041720 PMid:15728813
45. Scrivener S, Goddard RV, Kaminski ER, Prentice AG. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003; 44: 383-389. http://dx.doi.org/10.1080/1042819021000029993
46. Christopoulos P, Pfeifer D, Bartholome K, Follo M, Timmer J, Fisch P, Veelken H. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood 2011; 117: 3836-3846. http://dx.doi.org/10.1182/blood-2010-07-299321 PMid:21270444
47. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, Knolle PA, Thomas RK, von Bergwelt-Baildon M, Debey S, Hallek M, Schultze JL. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106: 2018-2025. http://dx.doi.org/10.1182/blood-2005-02-0642 PMid:15914560
48. Giannopoulos K, Schmitt M, Kowal M, Wlasiuk P, Bojarska-Junak A, Chen J, Rolinski J, Dmoszynska A. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008; 20: 677-682. PMid:18695923
49. Deutsch V, Pierry C, Polliack A. Expansion of regulatory T cells in B chronic lymphocytic leukemia: enhanced 'brakes' on host immunity. Leuk Lymphoma 2009; 50: 687-688. http://dx.doi.org/10.1080/10428190902954389
50. Jak M, Mous R, Remmerswaal EBM, Spijker R, Jaspers A, Yague A, Eldering E, van Lier RAW, Van Oers MHJ. Enhanced formation and survival of CD4+CD25highFoxP3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50: 788-801. http://dx.doi.org/10.1080/10428190902803677
51. D'Arena G, Laurenti L, Minervini MM, Deaglio S, Bonello L, De Martino L, De Padua L, Savino L, Tarnani M, De Feo V, Cascavilla N. Regulatory T-cell number is increate in chronic lymphocytic leukemia patients and correlate with progressive disease. Leuk Res 2011; 35: 363-368. http://dx.doi.org/10.1016/j.leukres.2010.08.010 PMid:20880586
52. Giannopoulos K, Schmitt M, Wlasiuk P, Chen J, Bojarska-Junak A, Kowal M, Rolinski J, Dmoszynska A. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia 2008; 22: 222-224. http://dx.doi.org/10.1038/sj.leu.2404869 PMid:17657216
53. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006; 108: 253-261. http://dx.doi.org/10.1182/blood-2005-11-4567 PMid:16537805 PMCid:1895836
54. Ramsay AG, Gribben JG. Immune dysfunction in chronic lymphocytic leukemia T cells and Lenalidomide as an immunodulatory drug. Haematologica 2009; 94: 1198-1202. http://dx.doi.org/10.3324/haematol.2009.009274 PMid:19734414 PMCid:2738710
55. Lee B-N, Gao H, Cohen EN, Badoux X, Wierda WG, Estrov Z, Faderl SH, Keating MJ, Ferrajoli A, Reuben JM. Treatment with Lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 2011; 117: 3999-4008. http://dx.doi.org/10.1002/cncr.25983 PMid:21858802
56. Weiss L, Melchardt T, Egle A, Grabmer C, Greil R, Tinhofer I.Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 2011; 117: 2163-2169. http://dx.doi.org/10.1002/cncr.25752 PMid:21523729
57. D'Arena G, D'Auria F, Simeon V, Laurenti L, Deaglio S, Mansueto G, Del Principe MI, Statuto T, Pietrantuono G, Guariglia R, Innocenti I, Martorelli MC, Villani O, De Feo V, Del Poeta G, Musto P. A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia. Am J Hematol 2012; 87; 628-631. http://dx.doi.org/10.1002/ajh.23170 PMid:22460620
58. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps JK. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute - Working Group 1996 Guidelines. Blood 2008; 111: 5446-5456. http://dx.doi.org/10.1182/blood-2007-06-093906 PMid:18216293 PMCid:2972576
59. D'Arena G, Rossi G, Minervini MM, Savino L, D'Auria F, Laurenti L, Del Principe MI, Deaglio S, Biagi A, De Martino L, De Feo V, Cascavilla N, Musto P, Del Poeta G. Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis. Int J Immunopathol Pharmacol 2011; 24: 915-923. PMid:22230398
60. Chatila TA. Role of regulatory T cells in human disease. J Allergy Clin Immunol 2005; 116: 949-959. http://dx.doi.org/10.1016/j.jaci.2005.08.047 PMid:16275360
61. Colombo MP, Piconese S. Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nature Rev 2007; 7: 880-887. http://dx.doi.org/10.1038/nrc2250 PMid:17957190
62. Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev 2008; 223: 371388. http://dx.doi.org/10.1111/j.1600-065X.2008.00637.x PMid:18613848
63. Nizar S, Copier J, Meyer B, Bodman-Smith M, Galustian C, Kumar D, Dalgleish A. T-regulatory cell modulation: the future of cancer immunotherapy? Br J Caner 2009; 100: 1697-1703. http://dx.doi.org/10.1038/sj.bjc.6605040 PMid:19384299 PMCid:2695683
64. D'Arena G, Deaglio S, Laurenti L, De Martino L, De Feo V, Fusco BM, Carella AM, Cascavilla N, Musto P. Targeting regulatory t cells for anticancer therapy. Mini-Rev Med Chem 2011; 11: 480-485. http://dx.doi.org/10.2174/138955711795843365 PMid:21561409
65. Wright GP, Ehrenstein MR, Stauss HJ. Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity. Expert Rev Clin Immunol 2011; 7: 213-225. http://dx.doi.org/10.1586/eci.10.96 PMid:2142625